The Splice Index as a prognostic biomarker of strength and function in myotonic dystrophy type 1
Authors:
- Marina ProvenzanoMPMarina Provenzano
- Kobe IkegamiKIKobe Ikegami
- Kameron BatesKBKameron Bates
- Alison GaynorAGAlison Gaynor
- Julia M. HartmanJHJulia M. Hartman
- Amanda ButlerABAmanda Butler
- Kiera N. BerggrenKBKiera N. Berggren
- Jeanne DekdebrunJDJeanne Dekdebrun
- Man HungMHMan Hung
- Dana M. LapatoDLDana M. Lapato
- Michael KieferMKMichael Kiefer
Open Access
- 31 December 2024
- journal article
- clinical trial
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (4)
Abstract
BACKGROUND: Myotonic dystrophy type 1 (DM1) is a multisystemic, CTG repeat expansion disorder characterized by a slow, progressive decline in skeletal muscle function. A biomarker correlating RNA mis-splicing, the core pathogenic disease mechanism, and muscle performance is crucial for assessing response to disease-modifying interventions. We evaluated the Myotonic Dystrophy Splice Index (SI), a composite RNA splicing biomarker incorporating 22 disease-specific events, as a potential biomarker of DM1 muscle weakness. METHODS: Total RNA sequencing of tibialis anterior biopsies from 58 DM1 participants and 33 unaffected/disease controls was used to evaluate RNA splicing events across the disease spectrum. Targeted RNA sequencing was used to derive the SI from biopsies collected at baseline ( n = 52) or a 3-month ( n = 37) follow-up visit along with clinical measures of muscle performance. RESULTS: The SI demonstrated significant associations with measures of muscle strength and ambulation, including ankle dorsiflexion (ADF) strength and 10-meter run/fast walk (Pearson’s r = –0.719 and –0.680, respectively). The SI was relatively stable over 3 months (intraclass correlation coefficient [ICC] = 0.863). Latent-class analysis identified 3 DM1 subgroups stratified by baseline SI (SI Mild , SI Moderate , and SI Severe ); SI Moderate individuals had a significant increase in the SI over 3 months. Multiple linear regression modeling revealed that baseline ADF and SI were predictive of strength at 3 months (adjusted R ² = 0.830). CONCLUSION: The SI is a reliable biomarker that captures associations of RNA mis-splicing with physical strength and mobility and has prognostic utility to predict future function, establishing it as a potential biomarker for assessment of therapeutic target engagement. TRIAL REGISTRATION: ClinicalTrials.gov NCT03981575. FUNDING: FDA (7R01FD006071), Myotonic Dystrophy Foundation, Wyck Foundation, Muscular Dystrophy Association, Novartis, Dyne, Avidity, PepGen, Takeda, Sanofi Genzyme, Pfizer, Arthex, and Vertex Pharmaceuticals.Keywords
All Related Versions
Funding Information
- U.S. Food and Drug Administration (7R01FD006071)
- Myotonic Dystrophy Foundation (N/A)
- Wyck Foundation (N/A)
- Muscular Dystrophy Association (N/A)
- Novartis (N/A)
- Dyne (N/A)
- Avidity (N/A)
- PepGen (N/A)
- Takeda (N/A)
- Sanofi Genzyme (N/A)
- Pfizer (N/A)
- Arthex (N/A)
- Vertex Pharmaceuticals (N/A)
This publication has 49 references indexed in Scilit:
- Molecular and cellular basis of calpainopathy (limb girdle muscular dystrophy type 2A)Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2007
- Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophyHuman Molecular Genetics, 2006
- Loss of the Muscle-Specific Chloride Channel in Type 1 Myotonic Dystrophy Due to Misregulated Alternative SplicingMolecular Cell, 2002
- Expanded CUG Repeats Trigger Aberrant Splicing of ClC-1 Chloride Channel Pre-mRNA and Hyperexcitability of Skeletal Muscle in Myotonic DystrophyMolecular Cell, 2002
- Three proteins, MBNL, MBLL and MBXL, co-localize in vivo with nuclear foci of expanded-repeat transcripts in DM1 and DM2 cellsHuman Molecular Genetics, 2002
- Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophyNature Genetics, 2001
- Recruitment of human muscleblind proteins to (CUG)n expansions associated with myotonic dystrophyThe EMBO Journal, 2000
- An Unstable Triplet Repeat in a Gene Related to Myotonic Muscular DystrophyScience, 1992
- Myotonic Dystrophy Mutation: an Unstable CTG Repeat in the 3′ Untranslated region of the GeneScience, 1992
- Molecular basis of myotonic dystrophy: Expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family memberCell, 1992